Gilead has a chance now to improve its position as well as re-evaluate approaches to cell therapy. Preferential treatment of
certain groups of employees must end.
Gilead has one of the highest revenues per employee, so it can afford mismanagement, bad strategies, dei, Kite drag, and other wasteful policies. Who pays for this? Patients, taxpayers and all thru insurance premiums.
Gilead has announced more than 100 person layoff coming, this time from the HQ location.
Streamlining ahead of a new administration, or as usual, a result of internal chaos and turmoil?
More layoffs would come in 2025.
layoff of 72, a small number comparing to company size, but be one of these.
Another proof how incompetent the pharma management is. Strategy, what strategy? Firstly they create a hype, hire many and then, oops!
